Indaptus Therapeutics, Inc. (INDP)
Nasdaq: INDP · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2021
Filings
236 filings since 2017 beside 108 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Jul 16, 2026.
Filings a yearinsider forms included
695533547261
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 11 times in the last 36 months, the newest Sep 4, 2026.Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Jan 31, 2025.SEC letters: 12 in the last 36 months, the newest Aug 19, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 13, 2026
10-Q
Quarterly reportThe SI's read Indaptus Therapeutics reported a third quarter net loss of $1,048,778, down from $2,975,117 a year earlier, as research spending fell to $271,204. Cash rose to $26,604,443 from $8,507,628 after a $12.0 million private placement in June and about $24.0 million raised in a September placement, while shares outstanding grew to 133,242,324 from 2,167,324. The tag is neutral because the stronger cash position came with heavy dilution and a shift away from its original cancer drug work toward sleep research and possible acquisitions.
Sep 30, 2026
Sep 10, 2026
8-K items 1.01, 3.02, 9.01
Major agreement signed; Shares sold without registration · Current report
Sep 8, 2026
Aug 13, 2026
8-K items 2.02, 5.07, 9.01
Results released; Shareholder vote · Current report
Aug 10, 2026
Jun 24, 2026
8-K items 1.01, 3.02, 9.01
Major agreement signed; Shares sold without registration · Current report
Jun 17, 2026
Apr 24, 2026
8-K/A items 5.02, 9.01
Officer or director change · Current report, amended
Apr 22, 2026
Mar 24, 2026
8-K items 5.01, 5.02, 9.01
Change of control; Officer or director change · Current report
Mar 18, 2026
40 of 236 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.